INTRODUCTION: Vascular endothelial growth factor A (VEGFA) and its kinase insert domain receptor (VEGFR2/KDR) were reported to be upregulated in chronic myeloid leukemia (CML); however, the influence of polymorphisms in VEGFA and VEGFR2 in CML pathogenesis and therapeutic response, have not yet been elucidated. METHODS: We aimed to analyze these polymorphisms in 212 CML patients and 212 healthy controls by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. RESULTS: The VEGFA+936C>T polymorphism did not differ significantly between the CML patients and controls. The frequency of CT genotype was higher in CML patients than in controls (25 vs. 18%), higher in males than in females (29 vs. 18%), was more prevalent in the patients with splenomegaly (p = 0.03), and was negatively associated with lactate dehydrogenase (LDH) levels (p = 0.01). The frequency of VEGFR2 mutant T-allele was higher in CML patients than controls (p < 0.0001). In the dominant model, patients having the combined AT and TT genotypes were associated with 2.6-fold higher risk of CML [odds ratio (OR) = 2.6, 95% confidence interval (CI) = 1.71–3.97, p < 0.0001]. VEGFR2 AT genotype was significantly associated with high blast count (p = 0.006), minor hematological response (p = 0.03) and poor cytogenetic response (p = 0.003), indicating its role in therapeutic resistance. In contrast, poor molecular response was observed in patients with TT genotype (p = 0.02). VEGFA+936C>T polymorphism was found to have synergistic interaction with VEGFR2+1416A>T in inflating the risk for CML further (P(interaction) = 0.0002). CONCLUSION: Our results indicate that VEGFR2+1416A>T polymorphism may be a useful marker in assessing the disease progression in CML patients. In addition, VEGFA+936C>T was observed to have additive effect in inflating the risk further.
INTRODUCTION:Vascular endothelial growth factor A (VEGFA) and its kinase insert domain receptor (VEGFR2/KDR) were reported to be upregulated in chronic myeloid leukemia (CML); however, the influence of polymorphisms in VEGFA and VEGFR2 in CML pathogenesis and therapeutic response, have not yet been elucidated. METHODS: We aimed to analyze these polymorphisms in 212 CMLpatients and 212 healthy controls by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. RESULTS: The VEGFA+936C>T polymorphism did not differ significantly between the CMLpatients and controls. The frequency of CT genotype was higher in CMLpatients than in controls (25 vs. 18%), higher in males than in females (29 vs. 18%), was more prevalent in the patients with splenomegaly (p = 0.03), and was negatively associated with lactate dehydrogenase (LDH) levels (p = 0.01). The frequency of VEGFR2 mutant T-allele was higher in CMLpatients than controls (p < 0.0001). In the dominant model, patients having the combined AT and TT genotypes were associated with 2.6-fold higher risk of CML [odds ratio (OR) = 2.6, 95% confidence interval (CI) = 1.71–3.97, p < 0.0001]. VEGFR2 AT genotype was significantly associated with high blast count (p = 0.006), minor hematological response (p = 0.03) and poor cytogenetic response (p = 0.003), indicating its role in therapeutic resistance. In contrast, poor molecular response was observed in patients with TT genotype (p = 0.02). VEGFA+936C>T polymorphism was found to have synergistic interaction with VEGFR2+1416A>T in inflating the risk for CML further (P(interaction) = 0.0002). CONCLUSION: Our results indicate that VEGFR2+1416A>T polymorphism may be a useful marker in assessing the disease progression in CMLpatients. In addition, VEGFA+936C>T was observed to have additive effect in inflating the risk further.
Authors: Niyaz A Naik; Imtiyaz A Bhat; Dil Afroze; Roohi Rasool; Hyder Mir; Syed Irtiza Andrabi; Sonaullah Shah; Mushtaq A Siddiqi; Zafar A Shah Journal: Tumour Biol Date: 2012-01-10
Authors: A Janowska-Wieczorek; M Majka; L Marquez-Curtis; J A Wertheim; A R Turner; M Z Ratajczak Journal: Leukemia Date: 2002-06 Impact factor: 11.528
Authors: Dita Gratzinger; Shuchun Zhao; Robert J Tibshirani; Eric D Hsi; Christine P Hans; Brad Pohlman; Martin Bast; Abraham Avigdor; Ginette Schiby; Arnon Nagler; Gerald E Byrne; Izidore S Lossos; Yasodha Natkunam Journal: Lab Invest Date: 2007-11-12 Impact factor: 5.662
Authors: Matthias Mayerhofer; Peter Valent; Wolfgang R Sperr; James D Griffin; Christian Sillaber Journal: Blood Date: 2002-07-18 Impact factor: 22.113
Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Bilal Abdulmawjood; Beatriz Costa; Catarina Roma-Rodrigues; Pedro V Baptista; Alexandra R Fernandes Journal: Int J Mol Sci Date: 2021-11-19 Impact factor: 5.923